A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms
NCT ID: NCT05128344
Last Updated: 2023-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2023-04-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Novel Approach to Infantile Spasms
NCT03347526
Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms
NCT03876444
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
NCT02299115
Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
NCT04302116
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
NCT02829827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMZ002
AMZ002 injectable solution, 0.5mg/mL
Injectable solution
Vigabatrin
Vigabatrin, oral
Oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMZ002 injectable solution, 0.5mg/mL
Injectable solution
Vigabatrin, oral
Oral administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has normal renal function as defined by an estimated glomerular filtration rate (eGFR) greater than \[\>\] 60 milliliter/minute (mL/min)/1.73 m\^2, calculated as eGFR = 0.413 × (height \[Centimeter (cm)\]/serum creatinine \[milligrams per deciliter {mg/dL}\])
* Participant's legally authorized representative (that is \[i.e.\], parent or guardian) must provide written informed consent obtained per Institutional Review Board (IRB) policy and requirements, consistent with the International Council for Harmonisation (ICH)
* Participant's parent/guardian is able to understand and willing to comply with study procedures and restrictions
Exclusion Criteria
* Participant has acute illness considered clinically significant by the Investigator within 30 days prior to Screening
* Participant has a diagnosis of recent systemic fungal infection; history of ocular herpes simplex; history of or current peptic ulcer; uncontrolled hypertension or congestive heart failure; or any other condition that would be significantly impacted by the study drug
* Participant has a preplanned surgery or procedure(s) that would interfere with the conduct of the study
* Participant has received any prior treatment for IS
* Participant has been previously treated with adrenocorticotropic hormone (ACTH), corticosteroids, or Vigabatrin for seizures;
* Participant has been previously treated with a course of corticosteroids for an indication other than seizures within 30 days prior to Screening
* Participant has a known or suspected allergy to ACTH or Vigabatrin or any component of AMZ002 or Vigabatrin
* Participant has used any other investigational drug within 30 days or 5 half-lives prior to the first dose of AMZ002 or Vigabatrin (whichever is longer)
* Participant' s parent/guardian is unable to provide written informed consent and/or to complete the daily diary
* Participant has any other disease, condition, or therapy that, in the opinion of the Investigator, might compromise safety or compliance, preclude the participant from successfully completing the study, or interfere with the interpretation of the results
2 Months
24 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amzell
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Childrens Hospital Colorado
Aurora, Colorado, United States
Miami Children's Hospital
Miami, Florida, United States
Advent Health Orlando
Orlando, Florida, United States
Arnold Palmer Hospital For Children
Orlando, Florida, United States
Childrens Healthcare of Atlanta
Atlanta, Georgia, United States
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
University of Kentucky Hospital
Lexington, Kentucky, United States
Children's Brain Institute
Lexington, Massachusetts, United States
Children's Hospital of Michigan
Detroit, Michigan, United States
Staten Island University Hospital, North
Staten Island, New York, United States
Wake Forest Baptist Medical Center - PPDS
Winston-Salem, North Carolina, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia
Buenos Aires, , Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Paediatric Hospital Dr. Juan P. Garrahan
Buenos Aires, , Argentina
CHU Bordeaux - Hopital des Enfants
Bordeaux, , France
HFME-Hospices Civils de Lyon
Bron, , France
Hopital Roger Salengro - CHU de Lille
Lille, , France
Hopital Necker - Enfants Malades
Paris, , France
Hopital de Hautepierre
Strasbourg, , France
All India Institute of Medical Sciences
New Delhi, Dehli, India
Indira Gandhi Institute of Child Health
Bangalore, Karnataka, India
Amrita Advanced Centre for Epilepsy
Kochi, Kerala, India
Bharati Vidyapeeth Deemed University - Bharati Hospital
Pune, Maharashtra, India
Azienda Ospedaliero Universitaria
Ancona, , Italy
Pediatric Hospital G. Salesi
Ancona, , Italy
AOU Anna Meyer - Clinica di Neurologia Pediatrica
Florence, , Italy
Istituto Pediatrico Giannina Gaslini
Genova, , Italy
Ospedale dei Bambini Vittore Buzzi
Milan, , Italy
Universita degli Studi di Napoli Federico II
Naples, , Italy
Ospedale Pediatrico Bambino Gesu
Roma, , Italy
Policlinico Universitario A.Gemelli
Roma, , Italy
Azienda Ospedaliera Universitaria Integrata
Verona, , Italy
Neurociencias Estudios Clinicos S.C.
Culiacán, , Mexico
HSRT
Mexico City, , Mexico
Tecnologico De Monterrey - Hospital Zambrano Hellion - Instituto de Neurologia y Neurocirugia
Nuevo León, , Mexico
The University Clinical Center
Gdansk, Gdansk, Poland
Provincial Specialist Children's Hospital st. Ludwika
Krakow, Krakow, Poland
Medical University of Warsaw
Warsaw, , Poland
Institute of Mother and Child
Warsaw, , Poland
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-003015-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AMZ002-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.